- Home
- ATOS vs RILY Comparison
ATOS vs RILY Comparison
Compare ATOS & RILY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- RILY
- Stock Information
- Founded
- ATOS 2009
- RILY 1973
- Country
- ATOS United States
- RILY United States
- Employees
- ATOS N/A
- RILY N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- RILY Investment Managers
- Sector
- ATOS Health Care
- RILY Finance
- Exchange
- ATOS Nasdaq
- RILY Nasdaq
- Market Cap
- ATOS 174.8M
- RILY 185.4M
- IPO Year
- ATOS 2012
- RILY 2007
- Fundamental
- Price
- ATOS $1.19
- RILY $4.83
- Analyst Decision
- ATOS Strong Buy
- RILY
- Analyst Count
- ATOS 3
- RILY 0
- Target Price
- ATOS $6.75
- RILY N/A
- AVG Volume (30 Days)
- ATOS 738.2K
- RILY 1.3M
- Earning Date
- ATOS 11-12-2024
- RILY 12-03-2024
- Dividend Yield
- ATOS N/A
- RILY 41.67%
- EPS Growth
- ATOS N/A
- RILY N/A
- EPS
- ATOS N/A
- RILY N/A
- Revenue
- ATOS N/A
- RILY $1,221,832,000.00
- Revenue This Year
- ATOS N/A
- RILY N/A
- Revenue Next Year
- ATOS N/A
- RILY N/A
- P/E Ratio
- ATOS N/A
- RILY N/A
- Revenue Growth
- ATOS N/A
- RILY 19.73
- 52 Week Low
- ATOS $0.70
- RILY $4.07
- 52 Week High
- ATOS $2.31
- RILY $40.09
- Technical
- Relative Strength Index (RSI)
- ATOS 31.91
- RILY 42.09
- Support Level
- ATOS $1.26
- RILY $4.52
- Resistance Level
- ATOS $1.66
- RILY $4.93
- Average True Range (ATR)
- ATOS 0.09
- RILY 0.37
- MACD
- ATOS -0.03
- RILY -0.04
- Stochastic Oscillator
- ATOS 4.08
- RILY 26.27
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About RILY B. Riley Financial Inc.
B. Riley Financial Inc is a diversified financial services company. The company through its subsidiaries offers investment banking and financial services to corporate, institutional, and high-net-worth clients and also asset disposition, valuation and appraisal, and capital advisory services to retail, wholesale, institutional, lenders, capital providers, private equity investors, and professional services firms in United States, Canada, and Europe. It also provides internet access and subscription services. The reportable operating segments of the company include Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications segment, and Consumer products segment.